Capecitabine

GPTKB entity

Statements (51)
Predicate Object
gptkbp:instanceOf gptkb:drug
antineoplastic agent
gptkbp:administeredBy oral
gptkbp:approvalYear 1998
gptkbp:approvedBy gptkb:Switzerland
gptkb:FDA
gptkb:EMA
gptkbp:ATCCode L01BC06
gptkbp:brand gptkb:Xeloda
gptkbp:CASNumber 154361-50-9
gptkbp:category antineoplastic agent
prodrug
pyrimidine analog
gptkbp:contraindication severe renal impairment
hypersensitivity to capecitabine
gptkbp:developedBy gptkb:Hoffmann-La_Roche
gptkbp:discoveredBy gptkb:Roche
gptkbp:eliminationHalfLife 0.85 hours
gptkbp:excretion urine
gptkbp:hasMolecularFormula C15H22FN3O6
https://www.w3.org/2000/01/rdf-schema#label Capecitabine
gptkbp:indication gastric cancer
metastatic breast cancer
metastatic colorectal cancer
adjuvant therapy for colon cancer
gptkbp:KEGGID D01219
gptkbp:legalStatus prescription only
gptkbp:mechanismOfAction inhibits DNA synthesis
inhibits thymidylate synthase
gptkbp:metabolism liver
gptkbp:pregnancyCategory gptkb:D_(Australia)
D (US)
gptkbp:prodrugOf gptkb:5-fluorouracil
gptkbp:proteinBinding 54%
gptkbp:PubChem_CID 60953
CHEMBL122
54998
DB01101
gptkbp:routeOfAdministration oral
gptkbp:sideEffect gptkb:hand-foot_syndrome
nausea
vomiting
diarrhea
fatigue
neutropenia
gptkbp:UNII 6804DJ8Z9U
gptkbp:usedFor gptkb:cancer
colorectal cancer
gastric cancer
gptkbp:bfsParent gptkb:NCT00239681
gptkbp:bfsLayer 7